This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
PURPOSE: Congenital venous malformations of the lower limbs represent a particular challenge for the vascular surgeon. Persistence of fetal veins is a rare malformation, and the most common is the ...
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Pulitzer Prize-nominated author Meryle Secrest makes the claim in the upcoming biography, 'Princess Margaret and the Curse' Janine Henni is a Royals Staff Writer for PEOPLE Digital, covering modern ...
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Dias–Logan syndrome (DLS) is a rare condition caused by heterozygous germline BCL11A pathogenic variants associated with global developmental delay, distinctive facial features, and asymptomatic ...
CAMBRIDGE, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, announces new safety and ...
Kansas schools are now required to show fetal development videos when human growth or sexuality is discussed. The law lacks specifics on implementation, leaving local districts with an unclear mandate ...
You might have wondered why some people with sickle cell disease seem to live relatively normal lives while others spend half their time in the hospital writhing in agony from pain crises. It’s the ...
CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback